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ABSTRACT 
Despite the advent of tyrosine kinase inhibitors, a proportion of chronic myeloid leukemia patients 
in chronic phase fails to respond to Imatinib or to second generation inhibitors and progress to 
blast crisis. Limited improvements in the understanding of the molecular mechanisms responsible 
for chronic myeloid leukemia transformation from chronic phase to the aggressive blast crisis were 
achieved until now. We present here a massive parallel sequencing analysis of 10 blast crisis 
samples and of the corresponding autologous chronic phase controls which reveals, for the first 
time, recurrent mutations affecting the ubiquitin-conjugating enzyme E2A gene (UBE2A, formerly 
RAD6A). Additional analyses on a cohort of 24 blast crisis, 41 chronic phase as well as 40 acute 
myeloid leukemia and 38 atypical chronic myeloid leukemia patients at onset confirmed that 
UBE2A mutations are specifically acquired during chronic myeloid leukemia progression with a 
frequency of 16.7% in advanced phases. In vitro studies show that the mutations here described 
cause a decrease in UBE2A activity, leading to an impairment of myeloid differentiation in chronic 
myeloid leukemia cells.  
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INTRODUCTION 
Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder with an incidence of 1-2 cases 
per 100000/year and is characterized by the presence of the BCR-ABL1 fusion gene, the product of 
the reciprocal translocation between chromosomes 9 and 22
1
. After the translocation, the coding 
regions of BCR and ABL1 genes are juxtaposed, leading to an enhanced ABL1 tyrosine kinase 
activity
2
. CML is a multi-step disease, evolving from a mild and easy to control form, called chronic 
phase (CP) to a very aggressive and incurable acute phase called blast crisis (BC). The majority of 
CML-CP patients are successfully treated with drugs able to impair BCR-ABL1 kinase activity 
(Tyrosine Kinase inhibitors-TKIs), thus confirming the central role of the oncogenic fusion protein 
in CML pathogenesis
3, 4
. However, a fraction of these patients fails to respond to the treatment 
(primary resistance) or becomes resistant after an initial response
4-6
. The persistence of BCR-ABL1 
activity typically drives the progression to the advanced phase of the disease within 3-5 years. One 
of the open issues in CML concerns the dissection of the molecular mechanisms driving the 
transformation to BC, commonly considered as a heterogeneous disease at molecular level
7-9
. BC 
is mainly characterized by the rapid expansion of the differentiation-arrested BCR-ABL1-positive 
blast cells
10
, therefore resembling an acute leukemia. In the major part of BC cases (~70%), blasts 
maintain myeloid features, while in 20-30% blast lineage is lymphoid. BCR-ABL1 expression, which 
increases during CML progression in conjunction with BCR transcription, seems to have a 
prominent role in this process, hyperactivating proliferative and anti-apoptotic signals and 
inducing genetic instability
5, 11, 12
. Previous reports showed the existence of a heterogeneous 
molecular signature among distinct BC patients
5, 7, 8
. However, these data were limited by the 
scarcity of matched CP/BC samples, due to the infrequent progression to BC after the advent of 
TKIs. Here we analyzed 10 paired CP/BC samples through a whole-exome sequencing (WES) 
approach, identifying somatic variants specific for BC progression since not present in the 
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autologous CP controls. Along with several mutations previously identified as BC driver events
5, 7, 
13
, we detected, for the first time, recurrent BC-specific mutations occurring on UBE2A gene. These 
data suggest that the appearance of UBE2A variants in CML cells could contribute to BC 
progression through the impairment of myeloid differentiation. 
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METHODS 
Cell lines 
The BA/F3-BCR-ABL1 and 32Dcl3-BCR/ABL1 cell lines were generated and maintained as described 
in
14, 15
. K562 and 293FT were purchased from DSMZ (Braunschweig, Germany) and Thermo-Fisher-
Scientific (Waltham, MA, USA) respectively, and were maintained following manufacturer 
instructions.  
Patients 
Diagnosis and staging were performed according to the World Health Organization WHO-2008 
classification
16
. Peripheral Blood (PB) or Bone Marrow (BM) of 10 matched CML chronic 
phase/blast crisis samples, 31 CP-CML, 14 AP/BC-CML, 38 atypical-CML (aCML) and 40 AML were 
collected at diagnosis and after obtaining written informed consent approved by the institutional 
ethics committee. The study was conducted in accordance with the Declaration of Helsinki. 
Samples were prepared as described in
17
. 
Whole Exome Sequencing (WES) 
Genomic DNA (gDNA) was extracted from purified cells with PureLink Genomic DNA kit (Thermo-
Fisher-Scientific). 1 μg of gDNA from each sample was fragmented (500bp) with a Diagenode-
Bioruptor sonicator system (Diagenode, Belgium) and processed according to the standard 
Illumina protocol. The Illumina TruSeq Exome Enrichment kit (Illumina Inc., San Diego, USA) was 
used to enrich the genomic libraries for the exonic regions and samples were sequenced as 
described in Supplemental Material. 
Plasmids, transfections and lentiviral infections 
BA/F3_BCR-ABL1-positive cells were transfected with pMIGR1_UBE2A vectors (Supplemental 
Material) as in 
14
 and were analyzed for GFP positivity with a FACSAria flow cytometer (BD 
Bioscience, San Jose, USA) and FACS-sorted when transfection efficiency was lower than 85 %. 
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32Dcl3-BCR/ABL1 cells were electroporated by using a Gene Pulser® II Electroporation System 
(BIORAD) with pMIGR1_UBE2A WT and I33M vectors as described in
14
  . 
To obtain stable UBE2A WT or I33M cell lines, GFP positive population was FACS-sorted with a 
MoFlo Astrios cell sorter equipped with Summit 6.3 software (both from Beckman Coulter, Miami, 
FL, USA). 
For UBE2A silencing, K562 cells were infected with lentivirus obtained from MISSION-shRNA 
pLKO.1-based vectors (TRCN0000320625) (Sigma-Aldrich, Missouri, USA) and packaged using 
293FT cell line. As a control, a pLKO.1MISSION non-target control vector (SHC002) (Sigma-Aldrich) 
was used. After infection K562 cells were maintained in 2µg/mL puromycin for selection of 
silenced (K562_shUBE2A) and control cells (K562_shNC).  
Quantitative Real-Time PCR (RT-qPCR) 
Total RNA was extracted using Trizol (Thermo-Fisher-Scientific) following manufacturer 
instructions. 1µg of total RNA was used to synthesize cDNA using Reverse Transcription Reagents 
(Thermo-Fisher-Scientific) after pre-treatment with DNAseI (Thermo-Fisher-Scientific) to avoid 
contamination from genomic DNA. Real-Time-Quantitative PCR (RT-qPCR) was performed using 
TaqMan® Brilliant II QPCR Master Mix (Agilent technologies, CA, USA) on a Stratagene-MX3005P 
(Agilent-technologies) under standard conditions. The housekeeping gene glucoronidase beta 
gene (GUSB) was used as an internal reference
12
. TaqMan® Gene Expression Assays (Thermo-
Fisher-Scientific) were used (Supplementary Table S1).  
In vitro-translation and ubiquitination assay 
In-vitro translation of UBE2A proteins was performed with 1-Step Human Coupled IVT Kit-DNA 
(Thermo-Fischer-Scientific) following manufacturer instructions. For ubiquitination assay we 
incubated 15µg of UBE2A proteins with 1µg of GST-Ubiquitin (Enzo-Life-Sciences, NY, USA), 0.2 ng 
of Ubiquitin Activating Enzyme (E1) (Enzo-Life-Science), 2mM ATP, Energy Regeneration Solution 
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(BostonBiochem, MA, USA), 2mM MgCl2, 2mM KCl, 16µg of BA/F3_BCR-ABL1 whole cell lysate in 
50mM TrisHCl (ph7.5). The reactions were incubated for 20 min at 37°C. The products were 
analyzed by Western Blotting.  
For the enzymatic activity of WT and mutated UBE2A 15µg of UBE2A in vitro synthetized protein 
were used. The AMP-Glo Assay (Promega catalog v5011) was used in order to quantify the amount 
of AMP generated by the ubiquitin conjugation machinery, composed by 170ng/µl Ubiquitin 
Protein, 15ng/µl UBA1 and 50 µM ATP (SignalChem). 
The production of AMP from ATP is directly proportional to the enzymatic activity of the 
ubiquitination machinery and therefore it was used to measure the ubiquitination in presence of 
WT and mutated UBE2A. The AMP signal was detected using the AMP Detection Solution 
(Promega) and a TECAN reading plate (Infinite F200Pro TECAN). 
Neutrophilic differentiation 
For induction of neutrophilic differentiation 32Dcl3-BCR/ABL1 UBE2A WT and I33M cells were 
treated as previously described
18
. 
32Dcl3-BCR/ABL1 cells expressing UBE2A WT or I33M were seeded at a density of 2x10
5 
cells per 
milliliter and cultured in presence of imatinib mesylate (1 µM final concentration) in combination 
with human recombinant GCSF (10ng/ml) or IL3 (0,5ng/ML). 
At day 3 and 6 cells were analyzed using FACS for CD11b surface expression and imaged with 
confocal microscopy (Supplementary material and methods). 
 
RESULTS 
Single nucleotide variants (SNVs) acquired during CML progression  
Genomic DNA (gDNA) from matched CP/BC samples was obtained for each patient at diagnosis 
(CP) and after progression to BC. Initially whole exome sequencing (WES) data from 10 patients 
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were analyzed. CP samples were used as baseline controls for each patient to identify somatic 
variants selectively occurring in BC (Table 1), thus allowing the recognition of molecular events 
occurring exclusively upon CML progression. By using this approach we identified mutations on 
genes already associated with BC, such as RUNX1, IKZF1, NRAS, ASXL1 and ABL1
7, 13
. A total of 41 
non-synonymous single nucleotide variants (SNVs) and small indels were identified, with a mean 
of 4.1 mutations/patient acquired upon BC progression. Of these events, 31 were transitions, 7 
transversions and 3 indels, with the C>T substitution being the most frequent (63.4%) 
(Supplementary Figure 1). In one patient (pt #7) no acquired exonic SNVs could be detected during 
CML progression. 
Analysis of SNVs data showed the presence of two recurrently mutated genes in this cohort: ABL1, 
with mutations F486S, E255V and T315I occurring on the BCR-ABL1 fusion gene and leading to TKI 
resistance (30%, C.I. 95% 0.574, 0.026), and UBE2A (Xq24), an E2-ubiquitin conjugating enzyme 
required for post-replicative DNA damage repair 
15
 (20%, C.I. 95% 0.447, 0.000), which has never 
been previously reported as mutated in CML patients. UBE2A mutations occurred on two non-
contiguous residues: D114V and I33M (Table 1, Table 2). Patient #3 (male) showed an UBE2A 
variant frequency of 93%, as expected given that the gene is localized on the X chromosome. 
Patient #8 (female) carried a heterozygous UBE2A mutation (mutation ratio: 39%). The high 
mutation ratio observed in both patients suggests that UBE2A is present in the dominant BC clone 
(Table 1).  
 
UBE2A mutations are recurrent and acquired in late CML 
The evidence of recurrent, somatic UBE2A mutations has never been reported in BC cases, 
however they were previously found in other clonal disorders both of solid and hematopoietic 
origin, confirming their potential role in tumor progression
19
. To further characterize the pattern 
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and the frequency of UBE2A mutations in a larger cohort of patients, we sequenced 31 additional 
CML CP samples at onset, 14 AP/BC, 40 Acute Myeloid Leukemia and 38 aCML samples. No 
evidence of UBE2A mutations could be found in CP, AML and aCML samples, while in two AP/BC 
samples somatic UBE2A variants D114Y and M34fs were detected. Globally, acquired UBE2A 
mutations could be detected in a total of 16.7% (4/24) advanced (AP/BC) CML cases (95% C.I. 1.78-
31.62) (Table 2).  
 
UBE2A mutations affect protein activity 
Polyphen-2 (http://genetics.bwh.harvard.edu/pph/)
20
, DANN
11
 and FATHMM-MKL
21
 analyses 
revealed that all the UBE2A variants identified were potentially damaging, as also suggested by the 
presence of a N-terminal frameshift variant (M34fs) in one of the patients (Table 2). To gain insight 
into the functional role of UBE2A mutations, we stably transfected the BA/F3_BCR-ABL1 cell line
14
 
with the wild-type (WT) and the mutated UBE2A variants, I33M and D114V. The level of UBE2A 
expression in stable transfectants was verified both at protein (Figure 1A) and mRNA levels (Figure 
1B).  
The analysis of the levels of ubiquitin-conjugated H2A, a known UBE2A substrate
22
, in total cell 
lysate revealed a decreased H2A ubiquitination for both UBE2A variants compared to WT (Figure 
1C), with the effect of I33M being more prominent. In line with these findings, suggesting a 
decreased UBE2A activity for both variants, ubiquitination assay performed with in vitro translated 
WT and mutated UBE2A proteins confirmed a decrease in ubiquitin-conjugating activity for 
mutants compared to the WT form (Figure 1D). To further support this indication, we developed a 
new in vitro assay based on the measurement of the AMP concentration as a proxy to assess the 
overall level of ubiquitination. This test was performed in presence of GST-Ubiquitin and of the E1 
Ubiquitin activating enzyme UBA1 together with WT or mutated UBE2A. This analysis revealed a 
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significant decrease in ATP consumption, and therefore in ubiquitin-conjugating activity, for 
UBE2A mutants compared to the WT form (Figure 1E: enzyme specific activity assay, 1.55 (p<0.01) 
and 1.53 (p<0.01) fold decrease in UBE2A D114V and I33M AMP concentration compared to 
UBE2A WT). 
 
Transcriptome analysis of UBE2A cellular models shows significant perturbation of downstream 
pathways related to myeloid development 
To identify the gene networks perturbed by the UBE2A knock-out, stable lentiviral UBE2A silencing 
models were generated (Figure 2A-B) in the human myeloid K562 cell line (K562-shUBE2A and 
K562-shNC cells for UBE2A silencing and scrambled control, respectively; Supplementary Figure 2). 
Whole-Transcriptome analysis (RNA-Seq) highlighted the presence of 168 differentially expressed 
genes, with 117 of them being downregulated and 51 upregulated (Figure 2C). Gene Set 
Enrichment Analysis (GSEA) showed significant enrichment for ontologies related to myeloid 
differentiation (Figure 2D) and neural development (Supplementary Figure 3). RT-qPCR on 
K562shNC/shUBE2A cell lines on a set of five differentially expressed genes (ITGB4, RDH10, 
CLEC11A, CSF3R, RAP1GAP) confirmed RNA-Seq data (Figure 2E). Interestingly, the colony 
stimulating factor 3 receptor (CSF3R) was potently downregulated in shUBE2A both at mRNA 
(12.5-fold down-regulation; Figure 2E) and protein levels (Figure 2F), hence suggesting that its 
down-modulation may play a role in the differentiation block that is ultimately responsible for the 
onset of the BC. Immunoblot analysis on CP/BC mononuclear cells from patient #3, which acquired 
the D114V-UBE2A mutation in BC phase, confirmed CSF3R down-modulation (Figure 2G).  
To confirm the expression signature identified in the UBE2A silencing models, we stably 
overexpressed UBE2A WT and I33M in the 32Dcl3-BCR/ABL1 murine myeloid cell line 
(Supplementary Figure 4). In line with the expression profile shown in K562 UBE2A silenced cells, 
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also in these cell lines we observed a comparable modulation in the previous analyzed set of five 
differentially expressed genes (Figure 2H; ITGB4 1.52 p<0.01, RDH10 1.30 p<0.05, CLEC11A 2.84 
p<0.01, CSF3R 0.25 p<0.05, RAP1GAP 0.27 p<0.01; data are reported as fold-change in UBE2A 
I33M compared to UBE2A WT), therefore supporting the hypotheses that 1) UBE2A mutations 
modulate the activity of the target protein in a loss of function manner and 2) UBE2A mutations 
may probably act as dominant negative variants. Comparison of our signature with known BC data 
(GEO _GSE47927 - HSC data were used for BC vs CP calculation) indicated the presence of a 
moderate positive linear correlation (Supplementary Figure 5; R
2
 = 0.234). Notably, CSF3R 
expression level resulted to be markedly decreased also in the reference BC database, with a Log2 
fold-change of -2.19. Globally, these data indicate that UBE2A mutations are directly responsible 
for the modulation of CSF3R, ITGB4, RDH10, CLEC11A and RAP1GAP expression. This hypothesis is 
also corroborated by the 32Dcl3 cell models.  
 
UBE2A activity is involved in myeloid differentiation 
Erythrocytes and megakaryocyte differentiation can be induced in K562 cells by treating with 
hydroxyurea or phorbol 12-myristate 13-acetate (PMA), respectively
23, 24
. Treatment of UBE2A-
silenced K562 cells with hydroxyurea showed a significant delay in the ability to differentiate into 
erythrocytes, as assessed by Glycophorin A (GYPA-CD235a) expression levels when compared with 
the scrambled control (Figure 3A-C: relative CD235a expression compared to shNC Fold Change at 
day 0: 0.54 ± 0.13, p<0.001; day 1: 0.70 ± 0.12, p<0.05; day 3: 0.61 ± 0.15, p<0.05). Fluorescence-
activated cell sorting analysis (FACS) showed a 45% decrease of GYPA surface expression in 
silenced cells compared to controls after 24hrs of treatment (Figure 3B). In line with these 
findings, induction of hemoglobin (HBB) production was almost completely suppressed in 
shUBE2A cells (6.6 fold relative decrease of HBB mRNA level at 24hrs of treatment: p<0.001) 
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further confirming the negative effect of UBE2A silencing on erythroid differentiation (Figure 3C). 
Similarly, treatment of K562 cells with the megakaryocytic-inducing agent PMA showed significant 
impairment of megakaryocyte differentiation in shUBE2A cells, as assessed by the expression 
levels of CD41 (33% downregulation of surface protein expression, p< 0.001) and CD44 (38% 
decrease at mRNA level; p< 0.01) after PMA treatment (Supplementary Figure 6).  
Neutrophilic differentiation was similarly tested in the 32Dcl3 BCR/ABL1 cell lines overexpressing 
UBE2A WT or I33M. Treatment of the UBE2A I33M cell line with GCSF + IL-3 showed a delay in 
neutrophilic differentiation, as assessed by CD11b expression levels when compared with both 
UBE2A WT or control (Figure 4A). Cells treated with IL-3 alone were used as an internal control. 
Fluorescence-activated cell sorting analysis (FACS) showed no difference in CD11b surface 
expression in UBE2A I33M cell line compared to controls after 3 days of treatment but showed a 
37% decrease at day 6 which was also confirmed by confocal microscopy analysis (Figure 4B).  
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DISCUSSION 
In line with previous results
5, 7, 9
, our analysis done on matched CP/BC CML samples showed 
considerable somatic heterogeneity in BC phase. In all the samples we detected a very low 
number of acquired SNVs, corresponding to an average of 4.1 non-synonymous mutations per 
patient, a frequency far below the average reported for other hematopoietic neoplasms, such as 
Acute Myeloid Leukemia (AML: 7.8) and Chronic Lymphocytic Leukemia (CLL: 11.9)
25
. This can be 
in part explained by the characteristics of our analysis, where somatic variants occurring in BC 
were filtered against those in CP, therefore filtering-out all the driver and passenger variants pre-
existing the evolution to BC. All BC samples showed the prevalence of transition events and, in 
particular, of C:G>T:A substitutions, accounting for 66.7% of all the SNVs (Supplementary Figure 1). 
Approximately 85% of the C:G>T:A transitions were part of a CpG dinucleotide. Cytosines in CpG 
sites are known to be affected by a high mutation rate, caused by a spontaneous deamination of 
methylated cytosines 
26
. This mutation pattern is also in accordance with a BCR-ABL1 dependent 
mutation signature, characterized by inhibition of the mismatch repair system (MMR) and by 
accumulation of reactive oxygen species (ROS), as previously reported
27
. Mutations in RUNX1 and 
IKZF1, both involved in hematopoietic differentiation, have already been detected in the advanced 
stages of CML
7
 and are confirmed here as specific markers for BC progression. Along with this, the 
XPO1 gene (exportin-1) mutated here in a single patient with the E571K substitution, is also 
frequently mutated in clonal hematological disorders, with the E571K mutation widely 
represented in chronic lymphocytic leukemia
28
. SNVs analysis showed the presence of a recurrent 
mutation affecting the UBE2A gene (Xq24) (pt#3 and pt#8). UBE2A is an E2-ubiquitin conjugating 
enzyme which has never been found mutated in CML. Interestingly the two patients harboring 
UBE2A mutations lacked any recognizable CNAs (Table 2). WES and targeted resequencing of a 
broader cohort showed that somatic UBE2A mutations are found in a significant fraction (16.7%) 
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of advanced CML phases, thus confirming the initial exome analysis and suggesting a driver role 
for UBE2A loss of function during disease progression.  
The Saccaromyces Cerevisiae UBE2A homolog Rad6 participates in DNA repair, sporulation and cell 
cycle regulation
29
; in mammals a role for UBE2A in the regulation of transcription and chromatin 
reorganization through post-translational histone modifications has been recently hypothesized
30
. 
Germline mutations of the UBE2A gene in humans have been associated with the X-linked 
Nascimento-type intellectual disability syndrome
31-33
. In order to understand the effect of UBE2A 
mutations in a BCR-ABL1-positive model, we tested the activity of exogenous UBE2A both in the 
WT or mutated forms (D114V and I33M) in BA/F3 BCR-ABL1-positive cell lines. We observed a 
reduced amount of mono-ubiquitinated histone H2A, a known UBE2A substrate, after over-
expression of mutated UBE2A compared to the WT (Figure 1C), which indicates that the UBE2A 
mutations analyzed in this study decrease the activity of the enzyme. This result has been further 
confirmed by in-vitro assays for Ubiquitination and enzymatic activity on total cell lysates (Figure 
1D and E), thus providing evidence of a damaging effect of the two mutations on UBE2A function. 
Accordingly, one of the four variants identified in our cohort is a N-terminal frameshift mutation, 
thus supporting this hypothesis. This evidence is further strengthened by the distribution of 
UBE2A mutations throughout the entire protein, a pattern that is more common for genes 
undergoing inactivation. Mutations in the UBE2A paralog UBE2B were not detected in this study, 
which suggests a specific role for UBE2A in chronic myeloid leukemia. Stable silencing of UBE2A in 
the BCR-ABL-positive K562 cell line or overexpression of the I33M mutated form in a BCR-ABL1-
positive 32Dcl3cl3 myeloid cell line showed profound down-modulation of CSF3R, a critical 
regulator of myeloid lineage differentiation and development
34, 35
. CSF3R, also known as 
granulocyte colony-stimulating factor receptor (GCSFR), is a member of the hematopoietin 
receptor superfamily
35
 and plays a key role in promoting neutrophilic differentiation but may also 
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support the development of different types of hematopoietic progenitors
34
. This suggests a 
potential role for CSF3R modulation in the suppression of myeloid differentiation in BC. Although 
the precise mechanism by which UBE2A controls CSF3R expression is at present unknown, our 
data suggest that UBE2A-mediated CSF3R regulation occurs at transcriptional level. Alteration of 
CSF3R transcription could occur either by a direct activity of UBE2A on CSF3R promoter through 
epigenetic mechanisms
36
 or indirectly by UBE2A-mediated ubiquitination of specific transcription 
factors. Further studies will be necessary to clarify this process and to establish the relevance of 
CSF3R deregulation in the impairment of CML cells differentiation. In line with these findings we 
showed that impairment of UBE2A function induces a delay in the differentiation of K562 and 
32Dcl3-BCR/ABL1 cells after PMA, hydroxyurea or GCSF treatment, suggesting an important role 
for UBE2A as a modulator of myeloid differentiation. 
In conclusion, in this work we identified recurrent, somatic UBE2A mutations occurring in a 
significant fraction of advanced CML cases. We propose that the acquisition of somatic UBE2A 
mutations affects myeloid developmental pathways, promoting a differentiation blockade. Further 
studies will be required to thoroughly dissect the molecular mechanisms responsible for these 
effects and to define possible therapeutic strategies for UBE2A-mutated BC-CML cases. 
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Table 1: Single Nucleotide Variants (SNVs) and indels identified by exome sequencing in BC 
samples and absent in the paired CP control (*: stop codon; OncoScore is a text-mining tool that 
scores genes according to their association with cancer based on available biomedical literature; 
higher scores correspond to a stronger association with cancer) 
  
Patient  Disease 
Progression 
Time to BC from CP  
at diagnosis 
(months) 
Gene name (aa 
substitution) 
Mutation 
ratio 
OncoScore
39
 
1 F Lymphoid 1 RTP2(A190V) 
KCNH3(A314V) 
53% 
59% 
10.22 
5.61 
2 F Myeloid 59 FAT4(R1698W) 
FUT3(R354C) 
RUNX1(K194N) 
57% 
48% 
68% 
57.19 
30.21 
73 
3 M Myeloid 74 SMARCA4(A945T) 
UBE2A(D114V) 
ABL1(F486S) 
55% 
93% 
50% 
48.69 
25.66 
85.8 
4 F Myeloid 41 PTPN11(G503V) 
AMER3(R709H) 
LAMA2(P1025S) 
GRIN3A(R1024*) 
SMC5(L1102*) 
MESDC2(E130del) 
CCDC40(S17L) 
41% 
41% 
49% 
41% 
27% 
45% 
34% 
41.25 
34.16 
10.79 
5.95 
24.13 
28.07 
8.89 
5 F nd 14 NRAS(Q61R) 
DEFB119(R42H) 
IKZF1(N159S) 
AK8(R125H) 
32% 
46% 
44% 
67% 
81.65 
0 
72.76 
18.39 
6 M Lymphoid 52 - -  
7 M Lymphoid - PPT1(V168A) 
MDH1B(A272T) 
GPR98(R1745C) 
CEL(E216Q) 
LRP4(D449N) 
CYP2B6(R145W) 
BCR(F615W) 
39% 
47% 
45% 
46% 
54% 
40% 
44% 
8.58 
0 
5.54 
18.97 
12.28 
15.77 
81.02 
8 F Myeloid 59 ASXL1(G641_fs) 
EPB41L3(P963L) 
FGFR4(V262M) 
UBE2A(I33M) 
37% 
37% 
39% 
39% 
77.48 
76.11 
46.29 
25.66 
9 F Lymphoid 4 ABL1(E255V) 
BARD1(G527_fs) 
BSN(R3264H) 
EFCAB4B(V643M) 
KRT7(R339W) 
AP5M1(D289N) 
XPO1(E571K) 
28% 
28% 
26% 
31% 
41% 
38% 
32% 
85.8 
83.5 
3.32 
20.44 
70.25 
0 
47.33 
10 F Myeloid 10 HMCN1(S1371L) 
ABCA13(T2019M) 
ABL1(T315I) 
53% 
53% 
45% 
16.1 
28.17 
85.8 
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Table 2: UBE2A SNVs and indels identified in BC samples and absent in the paired CP control 
 
  
Chr Position Re
f 
Var Codon AA 
Change 
Polyphen
2 HDIV 
DANN 
Score 
Fathm
m 
MKL 
phastCons7 
Vertebrate 
chrX 119574955 A G ATA->ATG Ile33Met D 0.992 N 0.999 
chrX 119583137 A T GAT->GTT Asp114Va
l 
D 0.993 D 1 
chrX 119583136 G T GAT->TAT Asp114Ty
r 
D 0.996 D 1 
chrX 119574957  Ins 
AT 
ATG->ATATG M34fs n.a. n.a. n.a. n.a. 
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Figure legends 
 
Figure 1. Activity of UBE2A mutants. A) Western Blot analysis of total cell lysates from BA/F3_BCR-
ABL cell lines stably transfected with pMIGR-UBE2A vectors encoding for wild-type (WT) or 
mutated (D114V or I33M) UBE2A. Empty vector has been used as negative control. B) RT-qPCR of 
total RNA extracted from BA/F3_BCR-ABL_pMIGR/UBE2A cell lines. The values are normalized on 
the EMPTY cells (*** p<0.001). C) Western Blot of total cell lysates from BA/F3_BCR-
ABL_pMIGR/UBE2A cell lines. The signal at 14KDa corresponds to histone H2A. The signal at 
~23KDa corresponds to monoubiquitinated histone H2A (mUbH2A) according to
37
. D) Western 
Blot analysis of the in-vitro ubiquitination reaction performed with in-vitro translated UBE2A (WT 
and mutated forms) and GST-ubiquitin on total BA/F3_BCR-ABL lysate. The graph on the right 
shows the densitometric analysis of GST-ub signal (>170KDa) from three independent experiments 
obtained with ImageJ software
38
. The fold change is obtained normalizing the signal on the WT 
sample (WT vs D114V * p=0.022; WT vs I33M ** p=0.0069). E) Histogram showing the enzymatic 
activity of in vitro expressed UBE2A using the AMP Glow assay (WT vs D114V * p=0,0056; WT vs 
I33M ** p=0.0036). 
 
Figure 2. UBE2A silencing in K562 cells. A) RT-qPCR analysis of total RNA extracted from K562 cell 
lines infected with a lentiviral based system for UBE2A silencing (shNC: scrambled negative 
control; shUBE2A: UBE2A silenced cells). Values are normalized on shNC cells (*** p<0.0001). B) 
Western Blot analysis of total cell lysates from K562_shNC and K562_shUBE2A cells. C) Heat map 
of RNA-sequencing data showing color-coded expression levels of differentially expressed genes in 
three distinct populations of K562-shUBE2A compared to control (shNC). D) RT-qPCR analysis in 
K562 cell lines of a subset of differentially expressed genes identified by RNA-sequencing. E) Gene 
set enrichment analysis (GSEA) of the shUBE2A transcriptome. F) RT-qPCR analysis in the 32Dcl3 
cell line of a subset of differentially expressed genes identified by RNA-sequencing. G and H) 
CSF3R protein levels in total cell lysate of K562 cells (G) and of BC/CP samples from patient #3, 
carrying UBE2A mutation in the BC phase (H).  
 
Figure 3. Induction of erythroid differentiation in UBE2A-silenced K562 cell line. K562 cells were 
treated with 400 µM hydroxyurea. A) CD235a immunofluorescence staining for UBE2A-silenced 
K562 (shUBE2A) and control (shNC) cells after hydroxyurea or mock (-) treatments for the 
indicated times. (scale bar: 25μm). B) Average intensity of CD235a signal obtained acquiring 10 
fields from two independent experiments for each sample (approximately 80 cells each). C) FACS 
analysis of CD235a levels in K562 cells in presence (red line) or absence (black line) of 
hydroxyurea. D) Quantification of CD235a and hemoglobin mRNA relative levels (HBB: 
Hemoglobin-subunit-beta) through qRT-PCR after hydroxyurea treatment.  
 
Figure 4. Induction of neutrophilic differentiation in UBE2A WT or I33M 32Dcl3 cell line. Cells were 
treated with IL-3 or GCSF. A) FACS analysis of CD11b staining after induction of differentiation at 
day 3 and 6. B) CD11b immunofluorescence staining for 32Dcl3 CTRL, UBE2A WT and I33M at day 
6 showing a clear reduction in UBE2A I33M CD11b staining (scale bar: 20μm). 
 
 




Supplemental Methods 
 
Validation of mutations and UBE2A target sequencing 
All variants detected by Next Generation Sequencing approach were validated by standard 
Sanger sequencing1 or Mass Spectrometry method adapted from2 for genes indicated by * 
in Table S3. Briefly, 100ng of gDNA was amplified with the High Fidelity Fast Start Taq 
polymerase (Roche, Indianapolis, IN, USA) following manufacturer instructions. Primers 
are listed in Table S3. Extension primers used for genes indicated by * were: ASXL1 
CTGCCATCGGAGGGG, EPB41L3 TTGGCAGTGTTTCACC, FGF34 
CCAACACCACAGCCG, BARD1 TCGACAGGCCGCAGACC, BSN 
CAAGGCTCCTTCCCTGGA, EFCAB4B GGCGGTGGCTGAGCAGC, KRT7 
GGGACATATCCTGCTTGCCCC, MUDENG CCCACTAAATGCAGAGTCAT, UBE2A 
CCGTCCGAGAACAACAT, XPO1 AAATAGATTTACCATGCATGAATT. The entire coding 
region of UBE2A gene was amplified from gDNA using three different set of primers listed 
in Table S3. 
 
Vector constructions and mutagenesis 
The pCMV6_AC_GFP plasmid (cod. RG204194) containing the coding sequence (CDS) of 
UBE2A isoform 1 was obtained from Origene Technologies (Rockville, MD, USA). The 
UBE2A_CDS was amplified with the High Fidelity Fast Start Taq Polymerase (Roche) 
following manufacturer instructions with these primers: Fw 
5’AATAAGATCTACCATGTCCACCCCGGCTCGGCG3’ , Rw 
5’AATACTCGAGCTAACAATCACGCCAGCTTTGTTCTACTATTG3’. The amplified product 
was subsequently digested with BglII and XhoI restriction enzymes (Roche) and cloned 
into the pMIGR1 vector3 (a kind gift from G. Cazzaniga, Tettamanti Foundation, San 
Gerardo Hospital), obtaining the pMIGR1_UBE2A_wt plasmid. Site directed mutagenesis 
was applied to create pMIGR1_UBE2A_D114V and pMIGR1_UBE2A_I33M plasmids by 
using the Pfu Ultra High Fidelity enzyme (Agilent Technologies, Santa Clara, CA, USA). 
The products were then digested with DpnI (Roche) and 2 μl were used to transform the 
competent TOP10 bacterial strain (Life Technologies). The presence of the mutations was 
confirmed by Sanger sequencing. The primers used for mutagenesis reaction were as 
follows: UBE2A_I33MFw 5’CGTCCGAGAACAACATGATGGTGTGGAACGC3’, 
UBE2A_I33MRw 5’ GCGTTCCACACCATCATGTTGTTCTCGGACG3’, UBE2A_D114VFw 
5’CATCCATACAGTCTCTGTTGGTTGAACCCAATCCCAATAGTCC3’, UBE2A_D114VRw 
5’GGACTATTGGGATTGGGTTCAACCAACAGAGACTGTATGGATG3’. 
The pT7CFE1-Chis-UBE2A vectors for in-vitro protein translation were prepared from 
pMIGR_UBE2A_wt, pMIGR_UBE2A_D114V and pMIGR_UBE2A_I33M. The 
UBE2A_CDS was amplified from the plasmids with the Q5TM High-Fidelity DNA 
Polymerase (New England BioLabs, Ipswich, MA, USA) following manufacturer 
instructions with these primers: Fw 5’CCCATATGATGTCCACCCCGGCTC3’ , Rw 
5’ACTCGAGCTAACAATCACGCCAG3’. 
The respective amplified products and the pT7CFE1-CHis expression vector (Thermo 
Fischer SCIENTIFIC, Life Technologies, Waltham, MA, USA) were digested with NdeI and 
XhoI restriction enzymes (New England BioLabs, Ipswich, MA, USA) and were ligated with 
T4  DNA Ligase. 
 
Western Blot 
Whole cell lysates and western blots were performed as previously described4. For histone 
analysis cells were directly lysed in Laemmli Buffer. The antibody used were: 
UBE2A(A300-281A)(Bethyl Laboratories Inc., Montgomery, TX, USA), ABL1(K-12) (Santa 
Cruz Biotechnology Inc, Dallas, TX, USA), H2A(ab18255) (Abcam, Cambridge, UK), Actin 
(A2066)(Sigma-Aldrich), GST (Sigma-Aldrich), CSF3R(ab126167) (Abcam). 
 Fluorescence Activated Cell Sorting Analysis (FACS) 
K562 or 32Dcl3-BCR/ABL1 cells were stained with CD235a-FITC (130-100-265, Mylteni 
Biotech, Germany), CD11b-APC or mock controls antibodies after differentiation induction 
according to manufacturer instructions 
At the defined time points cells were washed twice  and resuspended in PBS  to a final 
concentration of 1 to 5x106 cells and incubated for 1h a RT with primary antibodies. 
Stained cells were analyzed on a BD FACSCanto I instrument. 
 
Fluorescent Imaging  
K562 cells or 32Dcl3-BCR/ABL1 were washed twice with PBS and fixed for 10 min at 25°C 
with 4% (w/v) p-formaldehyde in 0.12M sodium phosphate buffer, pH7.4, incubated for 1 h 
with primary fluorescent conjugated antibodies (CD235a-FITC, 130-100-265, Mylteni 
Biotech; CD41-FITC, SAB4700372, Sigma-Aldrich and CD11b-APC BD Bioscience) in 
GDB buffer [0.02M sodium phosphate buffer, pH7.4, containing 0.45M NaCl, 0.2% (w/v) 
bovine gelatine] and counterstained with DAPI. After two wash with PBS, labelled cells 
were mounted on glass slides with a 90% (v/v) glycerol/PBS solution. Images were 
acquired with a LSM710 confocal microscope (Carl Zeiss) and analysed with ImageJ 
software (https://imagej.nih.gov/ij/). 
 
Whole Exome Sequencing (WES) and Copy Number analysis 
Samples were sequenced as described in5. WES was performed with a mean coverage of 
60X. Image processing and basecall were performed using the Illumina Real Time 
Analysis Software. Paired Fastq files were aligned to the human reference genome 
(GRCh37/hg19) using the BWA aln/sampe algorithms6. Duplicates were removed using 
Rmdup. Quality of the aligned reads, somatic variant calling and copy number analysis 
were performed using CEQer2, an in-house evolution of CEQer tool7 as previously 
described5,8. Splicing variants were analyzed using SpliceFinder9. Variants were annotated 
using dbSNP147. All the filtered variants, exported as vcf files, were annotated using 
Annovar10 and manually inspected. To specifically identify variants present in the majority 
of BC cells and therefore likely playing a critical role in the progression, we included 
variants with a relative frequency ≥25%. 
 
RNA-Sequencing 
RNA libraries were generated from 2 μg total RNA extracted with TRIzol reagent (Life 
Technologies-Thermo Fisher Scientific, Waltham, MA USA) following manufacturer 
instructions. Libraries were sequenced as described in5. A total of three clones was 
selected for RNA-Seq analysis of both K562shNC and K562shUBE2A cell lines. Padj≤0.05 
was used as the main criteria to identify significantly deregulated genes with a Fold 
change ≥1.5 or ≤ 0.75.  Image processing and basecall was performed using the Illumina 
Real Time Analysis Software. Paired Fastq files were aligned to the human genome 
(GRCh38/hg38) by using STAR11, a splice junction mapper for RNA-Seq data, together 
with the corresponding splice junctions Ensembl GTF annotation, using the following 
parameters: --runThreadN 8 --outReadsUnmapped Fastx --outFilterType BySJout --
outSAMattributes NH HI AS nM MD --outFilterMultimapNmax 20 --alignSJoverhangMin 8 -
-alignSJDBoverhangMin 1 --outFilterMismatchNmax 999 --outFilterMismatchNoverLmax 
0.04 --alignIntronMin 20 --alignIntronMax 1000000 --alignMatesGapMax 1000000 --
alignTranscriptsPerReadNmax 100000 --quantMode TranscriptomeSAM GeneCounts --
limitBAMsortRAM 16620578182 --outSAMtype BAM SortedByCoordinate --
chimSegmentMin 20 --chimJunctionOverhangMin 10.  
 
 
Chemical compounds 
Phorbol 12-myristate 13-acetate (PMA) and Hydroxyurea, Granulocyte colony-stimulating 
factor (GCSF human) and IL-3 were obtained from Sigma-Aldrich(St.Louis, MA, USA). 
 
Supplemental data 
 
Table S1 
List of the Taqman Gene Expression Assays used in the study 
 
 Human Mouse 
UBE2A Hs_00163308_m1  
ITGB4 Hs_01103156_m1         Mm01266840_m1 
RDH10 Hs_00416907_m1         Mm00467150_m1 
CSF3R Hs_01114430_g1           Mm00432735_m1 
CLEC11A Hs_00998294_g1 Mm01206715_m1 
RAP1GAP Hs_00937964_g1          Mm01181224_m1 
CD44 Hs_01075864_m1  
CD235a Hs_00266777_m1  
HBB Hs_00747223_g1  
ITGA2B Hs_01116228_m1  
 
 
  
Table S2 List of all the primers used for the analysis (* analyzed by mass 
spectrometry) 
  
 GENE FORWARD PRIMER  REVERSE PRIMER Genomic 
Position, 
substitution 
RTP2 GGCAGGACTGAGGAAGGAGAAC GCTGGAGGAGGAGGTGACCAC Chr3: 187416394-
187416395, C/T 
KCNH3 CAGGTGTCCAGGCAAGAGTG CTGCTCTCGATCTCCCGCTGGC Chr12: 49937814-
49937815, G/A 
FAT4 CATTGGCACAAACGTGATATC ATGTAACTCTCTGTTAGCCTTTGAC Chr4: 126242657-
126242658, C/T 
FUT3 CTAGCAGGCAAGTCTTCTGGAGG CCCAGCAGAAGCAACTACGAGAG Chr19: 5843790-
5843791, G/A 
RUNX1 GCTTTGAGTAGCGAGAGTATTGAC GGTAACTTGTGCTGAAGGGCTG Chr21: 36231801-
36231802, T/A 
SMARCA4 CCCGCAGATCCGTTGGAAGTAC GCCTACAGCACGCTACAGCCTCTAG Chr19: 11132616-
11132617, G/A 
UBE2A  CATGCGGGACTTCAAGAGGTTGC CAATCACGCCAGCTTTGTTCTAC ChrX: 118717099-
118717100, A/T 
UBE2A(I33M) ACGTTGGATGAGACTCACCCGAAAATGACC ACGTTGGATGTGTCTTCCCGAAGGTTGCAG ChrX: 118708918-
118708919, A/G 
ABL1 (F486S) CTTGTTGCAGCAAAAGATGGTTAG GCTGGTCTGTGAACTTTCACCAG Chr9: 133755487-
133755488, T/C 
ABL1 (T315I)* CTTGTTGCAGCAAAAGATGGTTAG GCTGGTCTGTGAACTTTCACCAG Chr9: 133748282-
133748283, C/T 
ABL1 (E255V) TGACCAACTCGTGTGGAAACTC TTCGTCTGAGATACTGGATTCCTG Chr9: 133738364-
133738364, A/T 
PTPN11 GGTGATTTGTTGGCAAGTGAGGG GCATGGCAGTTCTTCAATCTGGCAG Chr12: 
112926887-
112926888, G/T 
FAM123C CGAGAGGAAGAGACACGAGGTCAC CACGGAGGTGACACTCTGGATGC Chr2:131521770-
131521771, G/A 
LAMA2 GTAGTACCCGAATATAAGGTGTTACAG CTTCATCATCTTTCCTACAAGTAAACTG Chr6: 129621915-
129621916, C/T 
GRIN3A GACTTGTCCTTTGATACTCCTCCAG CCATGACACCCTAGCAGGTAGTCTG Chr9: 104335733-
104335734, G/A 
SMC5 CTTACAGCTCCTGCAAAATCTTCC CCAAGAACTCAAGTTCAACCAAGAC Chr9: 72967244-
72967245, T/A 
MESDC2 TAGGCAACAAGAGCAAAACTCTGTC TCTTCCAGAGCACAAGAGACCTTC Chr15: 81274346-
81274347, C/-CT 
CCDC40 CAAACAGGACAAAGACGTGACAAC TCCTAACCTCATGTGATCCACCTG Chr17: 78011941-
78011942, C/T 
NRAS CCTAGATTCTCAATGTCAACAACC ACTGGGTACTTAATCTGTAGCCTCC Chr1: 115256528-
115256529, T/C 
DEFB119 CCTGACTCAATAGCCTCTCCTGC GCTAGGAAGACAGAAGGGTGAG Chr20: 29976969-
29976970, C/T 
IKZF1 GATCAAATTGACCCAGCCAGTG GTGAGACTTCTGTGTGTGTATGTGC Chr7: 50450291-
50450292, A/G 
AK8 CCTGTCATTAAATGCTTTCCTGTG GATGGAGCACGGGAAGTAGCACC Chr9: 135730271-
135730272, C/T 
PPT1 CTCTTCCTATGTCTCCAGCAATG CCTCAGGTAGTCCACCCACCTC Chr1: 40557017-
40557018, A/G 
MDH1B CCAGATACTCAGAATGTTCCTAGAGG GAGACCCAAGACCTGGCATCTC Chr2: 207619827-
207619828, G/A 
Chr2: 207619828-
207619829, C/T 
GPR98 GTTCTCCACAGGGCTGCCTCC GAGTCACTATGTTCCAGGTACAGTG Chr5: 89971181-
89971182, C/T 
CEL CCAGCAACCAACGTGACCTAG CCAGGATAAAGAACGGAAATGTGG Chr9: 135942014-
135942015, G/C 
LRP4 GACACAACCTCCTCCACGTTGC GCCACTCTTCTGGTACTGATGC Chr11: 46916334-
46916335, C/T 
CYP2B6 GACTCAGAGCCTTCTTCCAACTTC CTCCAGTTTCGTCTGTCTCTGTC Chr19: 41510299-
41510300, C/T 
BCR GAGCAGGTGGGAGGGAGCAG CACAGGGCTGACGCAACGAAC Chr22: 23610684-
23610685, T/G 
ASXL1* ACGTTGGATGTCTGCCACCTCCCTCATCG ACGTTGGATGATAGAGAGGCGGCCACCAC chr20:31022441-
31022442, -/G 
EPB41L3* ACGTTGGATGGAACTACTGGCACTTCCTTC ACGTTGGATGCGGAAACCATCAGTTTTGGC Chr18: 
5396285/5396286, 
G/A 
FGFR4* ACGTTGGATGTACACCTTGCACAGCAGCTC ACGTTGGATGCATCCTGCAGGCCGGGCTC Chr5: 176519378-
 
  
176519379, G/A 
BARD1* ACGTTGGATGTGAGTCGAGTCACACATTTG
    
ACGTTGGATGTCTGTATAATCGACAGGCCG
    
Chr2: 215617269-
215617270, 
C/+CGGTT 
BSN* ACGTTGGATGTACTGCTCCTGATAGCCAAC ACGTTGGATGGTCAAGGACACCTGGTTCTC Chr3: 49699069-
49699070, G/A 
EFCAB4B* ACGTTGGATGAAATGCTCCTAGGAAGGTCG ACGTTGGATGTCACAGACAAGCAGTCGTTC Chr12: 
3736607/3736608, 
C/T 
KRT7* ACGTTGGATGTCAAGGATGCTCGTGCCAAG ACGTTGGATGATGAGTTCCTGGTACTCACG Chr12: 52639298-
52639299, C/T 
MUDENG* ACGTTGGATGTCACCCTTGTGTAACTTCTC ACGTTGGATGTGGAAATTTGTAAGGCCCAC Chr14: 57747057-
57747058, G/A 
XPO1* ACGTTGGATGGTTTTTTGAGAGCTCACTGG ACGTTGGATGAGAAAGAGATTTACCATGC Chr2: 61719472-
61719473, C/T 
HMCN1 CTTTAGACACTGGGCAATA AATAGTGCTGCTTTCAGTCA  Chr1: 185970471-
185970472, C/T 
UBE2A_CDS1 CTCTCTCTGCTCTCAGGTTGGTTC ATTCCACTCAAGCCTTTAGCAG - 
UBE2A_CDS2 CTTTCCTCTCTACCCTGTATCTTTG TCTAGGACAAGACAGCCACAGAC - 
UBE2A_CDS3 CTGATTTCCTGGATAATAGGGCAGC AAGGAAGATGGAAACAGCACAACAG - 
Supplemental Figures 
                  
Figure S1. Graphic representation of somatic single nucleotide variants as frequency on 
the total of non-synonymous variants identified in the 10 BC samples. 
  
  
Figure S2. RT-qPCR for UBE2A expression levels in K562_shUBE2A and controls (shNC) 
populations selected for RNA-seq analysis. Beta-glucoronidase (GUSB) gene has been 
used as internal reference. 
  
  
Figure S3. Gene set enrichment analysis (GSEA) from RNA-seq data of differentially 
expressed genes comparing K562_shUBE2A with controls (shNC) displaying three of the 
most enriched categories associated with neuronal development.  
  
  
Figure S4. Expression of UBE2A WT and I33M in the BCR-ABL1-positive 32Dcl3. A) 
Western Blot analysis of total cell lysates from BCR-ABL1-positive 32Dcl3 cell lines stably 
transfected with pMIGR-UBE2A vectors encoding for the UBE2A (isoform 1) wild-type 
(WT) or I33M form. Empty vector has been used as negative control. B) RT-qPCR of total 
RNA extracted from BCR-ABL1-positive 32Dcl3 pMIGR/UBE2A cell lines. The values are 
normalized on the EMPTY cells (Empty vs WT *** p<0.001 and Empty vs I33M **p<0.01). 
 
  
 Figure S5: Linear correlation of Log2FC of 32Dcl3-BCR/ABL1 UBE2A WTvs 32Dcl3-
BCR/ABL1 UBE2A I33M (y-axys) and known BC data (GEO_GSE47927) vs HSC data (x-
axys) target genes; R2 = 0.234. 
 
  
 Figure S6. A) Immunofluorescence staining for CD41 in UBE2A-silenced-K562 
(shUBE2A) and controls (shNC) after 72 hours of Phorbol 12-myristate 13-acetate (PMA) 
treatment at 10nM. Green: CD41-FITC; Blue: DAPI. The graph represents the average 
intensity of CD41 signal obtained from acquiring 10 fields from two independent 
experiments for each sample (approximately 100 cells each). B-C) CD41 and CD44 
mRNA expression level assessed through RT-qPCR in PMA treated (+) and untreated 
K562 cells. Beta-glucoronidase (GUSB) gene has been used as internal reference. 
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